[New migraine treatment requires better health care structure]

Headache disorders are the most common neurological disorders during active life. They cause a great impact on health and well-being of many individuals in Sweden as well as large social costs and impact on private and working life. A new drug, monoclonal antibodies towards the CGRP receptor, is on the market and brings new opportunities to migraine care. The article summarizes a new treatment plan for the basic care of migraine patients and how the new drug should be managed. We also highlight how the introduction of new advanced therapies needs a well-organized health care organization.